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$977, and cardiovascular illness $35. The incremental
cost of diabetes co-occurring with psychosis was signifi-
cantly higher than all other disease co-occurrences. Dif-
ferences in the incremental cost of diabetes were not sta-
tistically significant between the other disease combinations.
ANCOVA was performed with longevity in the program
as a covariate to adjust for differential enrollment time.
CONCLUSION: The cost and management of chronic
conditions such as diabetes may be highly influenced by
other chronic conditions the patient may have. Disease
management programs may incorporate co-morbidity re-
search and models when evaluating the cost and treat-
ment of chronic conditions.
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OBJECTIVE: To obtain a profile of adult patients at risk
for nonsteroidal anti-inflammatory drug (NSAID) in-
duced gastrointestinal (GI) complications in a large man-
aged care health plan in the Southwest United States.
METHODS: Patients with NSAID prescription claims
between July 1996 and June 1997 were identified from a
health plan claims database. Patients with claims associ-
ated with ICD-9 and CPT codes indicating serious GI
complications were then identified. The ICD-9 codes
used were those associated with GI ulcers (531.x, 532.x,
533.x, and 534). A total of 19 CPT codes for GI proce-
dures indicative of a GI complication were used. A for-
ward stepwise logistic regression analysis, using the likeli-
hood-ratio (LR) test, was performed to identify predictors
of GI complications. Predictors included in the model
were individual NSAIDs and the following potential risk
factors: age, gender, previous GI drug usage, previous
steroid usage, and total days supply of NSAIDs during
the study period. RESULTS: A sample of 15,772 patients
with prescription claims for NSAIDs was identified. Of
these patients, 213 (1.4%) had an ICD-9 or CPT code
suggestive of serious GI complications secondary to a
NSAID. The logistic regression results indicated that
women (OR  0.65, 95% CI  0.48–0.87) were less
likely to develop GI complications. However, patients
with previous GI drug usage (OR  5.97, 95% CI 
4.51–7.90), those who used ketorolac (OR  2.01, 95%
CI  1.10–3.67) and those who used oxaprozin (OR 
1.82, 95% CI  1.10–3.00) were more likely to develop
GI complications. CONCLUSION: Users of ketorolac
and oxaprozin, as well as those with previous GI drug us-
age were at a higher risk, while women were at a lower
risk of GI complications in this managed care population.
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OBJECTIVES: The primary objective was to describe the
cost of illness of gastroesophageal reflux disease (GERD)
in a managed care population. Secondary objectives were
to characterize GERD costs and to quantify the depen-
dence of costs on disease severity. METHODS: This ret-
rospective study utilized claims data from a large (1.4
million lives) Midwest USA health care plan. Study popu-
lation had complete medical and pharmacy coverage con-
tinuously from 1996 to 1998 and possessed at least one
medical claim for GERD. Claim costs were compiled for
all GERD-attributable medical and drug claims. Costs
were also categorized by health care sector, such as hos-
pital inpatient or pharmacy. ICD-9 codes were used to
categorize subjects’ GERD into four progressively worse
states plus a non-symptomatic state: GERD0 {no GERD
claims}, GERD1 {mild esophagitis}, GERD2 {reflux esoph-
agitis}, GERD3 {esophageal ulceration}, and GERD4 {stric-
tures and complications}. RESULTS: A total of 7575 sub-
jects meeting the inclusion and exclusion criteria were
identified. The median age was 50 and there were 50%
females. Over the three year study period, more than $23
million was spent on GERD-related claims, or $86 per
subject per month. Pharmacotherapy contributed 31% of
GERD health care costs, inpatient hospital charges 37%,
outpatient facility charges 26%, and doctor office charges
6%. Mean cost per month was highly dependent on GERD
disease state: GERD0 cost $38 per month, GERD1 was
$189, GERD2 was $232, GERD3 was $536, and GERD4
was $412. At higher GERD states, pharmacotherapy was
a lower contributor to cost. CONCLUSIONS: For payers
of health care, GERD is an expensive disorder to manage.
Overall costs associated with GERD increase with the se-
verity of the disease, although the relative contribution of
each health care cost sector changes with disease severity.
INFECTIOUS DISEASE
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OBJECTIVE: To model the relationship between resis-
tance to trimethoprim sulphamethoxazole (TMP-SXT)
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and outcome of pyelonephritis from an RCT comparing
TMP-SXT with ciprofloxacin (Talan, JAMA, 283:1583–
1590,2000). METHODS: In the trial cost analysis was
limited to a comparison between the two treatment
groups, which did not permit analysis of effect modifiers,
such as TMP-SXT resistance. A probabilistic model was
developed and distributions were assigned to expected
costs and probabilities of cure, failure (persistent or re-
current infection) and superinfection (reinfection with a
new organism) from the trial data. These distributions,
which characterise the second order uncertainty sur-
rounding these outcomes following the trial, were propa-
gated through the model using Monte Carlo simulation
in order to generate cost-effectiveness acceptability curves.
RESULTS: There were 255 patients in the per protocol
analysis. The mean cost for patients with treatment fail-
ure ($476, n  34) was significantly higher than the cost
for patients who were either cured ($307, n  174) or
had superinfection ($325, n  11). However, treatment
with ciprofloxacin reduced both the probability and cost
of treatment failure (the mean difference in treatment
cost between success and failure was only $4 in the cipro-
floxacin arm compared with $267 in the TMP-SXT arm).
The probability that ciprofloxacin was dominant (greater
efficacy at lower cost) was 95% at 18% TMP-SXT re-
sistance and remained 95% down to a resistance rate of
10%. These results were sensitive to a small number of
hospitalisations (1 ciprofloxacin, 5 TMP-SXT). Taking
outpatient costs alone, the threshold value of treatment
failure at which ciprofloxacin was 90% likely to be cost-
effective ranged from $700 for 18% resistance to $350
for 30% resistance. CONCLUSIONS: The stochastic model
produces results that are importantly different from a
simple analysis based on point estimates of probability
and cost, particularly if the latter assumes that the cost of
treatment failure is the same for both treatments.
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BACKGROUND: There is increasing concern about the
potential effects of the lipodystrophy syndrome on the health
and quality of life of HIV-infected patients. OBJECTIVE:
Understand patients’ perception of the significance of the
lipodystrophy syndrome’s quality-of-life effects. DESIGN:
Cross-sectional study of volunteer HIV-infected patients.
SETTING: An urban, university-affiliated HIV clinic in
San Diego, California. Patients: 75 well-educated, predom-
inantly male, HIV-infected patients. MEASUREMENTS:
Patients’ beliefs about the importance of appearance upon
quality of life and preferences for hypothetical states per-
formed using the standard gamble and time trade-off
methods. RESULTS: Almost all patients (95%) indicated
that appearance was important to their quality of life,
and 89% agreed that they would be “really bothered” if
their HIV diagnosis were revealed by their appearance.
Patients were willing, on average, to give up 2 years (s.d.
2.8), out of a 10-year life-expectancy, to live in good
health rather than live with the syndrome, over and
above what they would give up to be free of symptoms
from HIV infection. Patients would take an additional
13% (s.d. 20%) risk of death to be cured of HIV infec-
tion when complicated by the syndrome (median increase
in risk, 9%), above the risk they would accept to be cured
of uncomplicated HIV infection. The amount that the pa-
tients would trade off was associated with beliefs about
the importance of their appearance to quality of life (p 
0.0045) and worry that their appearance would expose
their diagnosis by (p  0.032). CONCLUSIONS: The
physical effects of the lipodystrophy syndrome are impor-
tant enough to cause many patients to consider accepting
considerable risks of death or trading off substantial life-
expectancy to avoid the syndrome. Physicians may need
to tailor HIV care to this aspect of patients’ preferences.
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OBJECTIVE: Intranasal influenza vaccine has proven
clinical efficacy and may be better tolerated by young
children and their families than an injectable vaccine.
This study determined the potential cost-effectiveness
(CE) of intranasal influenza vaccine among healthy chil-
dren. METHODS: The CE analysis included clinical and
medical utilization data collected in 1996–8 during a pro-
spective 2-year efficacy trial of intranasal influenza vac-
cine. These data were supplemented with data from the
literature where necessary. The analysis included both di-
rect and indirect costs. The trial enrolled 1,602 healthy
children 15–71 months of age in year 1, 1,358 of whom
were enrolled in year 2. Children received 1 or 2 doses of
either intranasal influenza vaccine or placebo. The main
outcome measure was cost per febrile influenza-like ill-
ness (ILI) day avoided. The base case assumed that the
vaccine was given twice in the first year and once each
year thereafter at a total cost of $20 for the vaccine and
its administration (i.e. per dose). RESULTS: Vaccinated
children had an average of 1.2 fewer ILI fever days over 2
years than unvaccinated children. In an individual-based
vaccine delivery scenario, CE was approximately $30/
febrile ILI day avoided with the vaccine, and ranged from
$10–$59/febrile ILI day avoided at a cost per dose of
